COOPER COMPANIES, INC.

COO · XNAS

CIK 711404fmd_080WRZH809WKGA85PCWB0DF42FManufacturing · Ophthalmic GoodsTemplate: Standard

Coverage: Nov 01, 2007 to Jul 31, 2026, 70 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	1,967	2,139	2,533	2,653	2,431	2,923	3,308	3,593	3,895	4,092
Cost of revenue	794	773	901	897	896	967	1,169	1,235	1,300	1,410
Gross profit	1,173	1,366	1,632	1,757	1,535	1,956	2,140	2,358	2,596	2,682
Research and development	65	69	85	87	93	93	110	137	155	172
Selling, general and administrative	723	799	973	996	993	1,211	1,342	1,501	1,534	1,628
Operating income	324	429	403	547	312	506	508	533	706	683
Interest expense	26	33	83	68	37	23	57	105	114	100
Other non-operating income (expense)	(2)	(2)	12	(1)	(9)	9	25	(15)	(9)	(16)
Income before taxes	296	394	332	477	267	492	475	413	582	567
Income tax expense	21	21	192	11	28	(2,453)	90	119	190	192
Net income from continuing operations	275	373	140	467	238	2,945	386	294	392	375
Net income	274	373	140	467	238	2,945	386	294	392	375
Net income to common shareholders	–	–	–	467	238	2,945	386	–	–	–